ITM secures supply deal with Clovis Oncology

2021 09 14 23 49 7847 Business Handshake 400

German radiopharmaceutical firm ITM Isotope Technologies Munich has signed an agreement to supply its EndolucinBeta no-carrier-added lutetium-177 radiopharmaceutical precursor to Clovis Oncology.

Under the five-year deal, Clovis will utilize EndolucinBeta for the clinical development of its FAP-2286 fibroblast activation protein (FAP)-targeted radionuclide therapy candidate, according to the companies. FAP-2286 consists of a targeting peptide that binds to FAP and a site that can be used to attach radioisotopes, such as lutetium-177 for therapeutic use, or gallium-68 for imaging use, the companies said.

FAP-2286 is currently being investigated in a phase I/II study in patients with advanced solid tumors. Additional terms of the agreement were not disclosed.

Page 1 of 548
Next Page